April 26, 2010 (FinancialWire) — Health Enhancement Products, Inc. (OTCBB: HEPI) has named Dr. Denis M. Callewaert its chief science officer.

Dr. Callewaert will chair the science advisory board that now includes Donald Armstrong; Eric Holland, and Jack Vanden Heuvel.

Callewaert holds a PhD in biochemistry and is professor emeritus at Oakland University, located in Rochester Hills, Michigan, where he also founded the university's Center for Biomedical Research and served as its executive director for nearly 20 years.

Health Enhancement Products, Inc. (OTCBB: HEPI) is a health and wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [clvloy]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.